Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.

Sermorelin

GHRH(1-29) · GRF(1-29)-NH2 · Sermorelin Acetate · Geref

Animal replicated

FDA-approvedGHRH Analog Growth Hormone Secretagogue Peptide

RouteInjectableFDA-approved

Evidence grade: Animal replicated

Effect demonstrated in multiple animal studies; human data sparse or extrapolated. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.

At a glance

What it is: GHRH(1-29) / GRF(1-29)-NH₂ / Sermorelin Acetate (Geref) — GHRH Analog, Growth Hormone Secretagogue, Peptide.
Why people use it: Used primarily for muscle and performance and sleep and recovery.
What the evidence supports: Sermorelin's short half-life and the nocturnal GH pulse are not competing constraints — they are designed for each other. The 10-12 minute half-life produces a brief, transient GHRHR stimulation that mirrors the natural GHRH pulsatile pattern from the hypothalamus. Pre-sleep administration delivers this stimulus precisely when the pituitary's natural GH-releasing program is most active.

If you only read one thing

Sermorelin is the most clinically validated GHRH analog for GH axis support, has the cleanest safety profile of any GH secretagogue, was genuinely FDA-approved for 18 years, and was withdrawn for purely commercial reasons. The somatostatin feedback mechanism makes it physiologically impossible to produce supraphysiological GH levels — a fundamental safety advantage over exogenous rhGH. It became the cornerstone of legitimate physician-supervised anti-aging peptide therapy through compounding pharmacies. Then the FDA placed it on Category 2 in September 2023, disrupting the only legal clinical access pathway that existed after Geref's commercial withdrawal. Sermorelin's regulatory trajectory — approved, withdrawn commercially, used legally through compounding for 15 years, then restricted, then apparently restored — illustrates how the most clinically appropriate compound for a well-established clinical application can be the most vulnerable to regulatory disruption when commercial development paths are absent.

Check interactions →

Published literature

0human trials1human study0animal0in vitro

Evidence reality check

Human evidence

1 human study

1 observational; RCT evidence not present in corpus.

Preclinical base

0 lab signals

0 animal; 0 in-vitro/mechanistic.

Evidence snapshot

Sermorelin's short half-life and the nocturnal GH pulse are not competing constraints — they are designed for each other. The 10-12 minute half-life produces a brief, transient GHRHR stimulation that mirrors the natural GHRH pulsatile pattern from the hypothalamus. Pre-sleep administration delivers this stimulus precisely when the pituitary's natural GH-releasing program is most active.

From the chapter quick-reference block.

Sermorelin is the most clinically grounded GHRH analog in this reference: genuinely FDA-approved twice, genuinely withdrawn for non-safety reasons, genuinely the cleanest pharmacological profile of any GH secretagogue. Its regulatory story is also a case study in how the most clinically appropriate compound for an application can navigate a hostile regulatory environment precisely because it has the legitimate safety track record that the process requires.

The central tension resolved: sermorelin's somatostatin feedback ceiling means it cannot produce supraphysiological GH regardless of dose — a fundamental safety advantage over exogenous HGH that the regulatory process failed to weight appropriately when it placed sermorelin on Category 2 in 2023. The compound that was demonstrably safe in formal clinical development, confirmed to have been withdrawn for commercial rather than safety reasons, and used by millions of patients through legitimate physician-prescribed compounding pharmacies for 15 years was classified as a significant safety risk — because the compounding pharmacy regulatory framework evaluated it by different criteria than the drug approval framework that had previously validated it. The subsequent restoration to Category 1 reflects the correction of that inconsistency.

For practitioners and patients in 2026: sermorelin remains the most physiologically appropriate GHRH analog for general GH axis support, with the best safety profile (somatostatin ceiling, no cortisol/prolactin/appetite co-effects, preserved pituitary function), a genuine clinical evidence base (FDA approval, Khorram trial, extensive compounding era clinical observation), and — as of the reported Category 1 restoration — returning legitimate access through compounding pharmacies. Its shorter half-life compared to CJC-1295 is a pharmacokinetic feature that produces the most physiologically natural GH pulsatility in the GHRH analog class; for anti-aging and somatopause applications where preserving natural GH rhythm is a therapeutic goal, this is an advantage rather than a limitation.

Categories

Muscle & Performance Sleep & Recovery Weight Loss & Metabolic Hormonal & HPTA

Properties

Active malignancy: hard stopWADA S2✓ FDA-approved✓ Human evidenceNot injectable

Half-life

Plasma half-life: approximately 10-12 minutes following subcutaneous injection — the shortest half-life of any major GHRH analog in common use

Evidence

CAnimal replicated

FDA Regulatory History

1990: FDA-approved for pediatric GH deficiency diagnosis (sermorelin stimulation test). 1997: FDA-approved for therapeutic treatment of idiopathic GH deficiency in children with growth failure (Geref, EMD Serono). 2008: EMD Serono voluntarily withdrew Geref from the US market for commercial/manufacturing reasons — not safety, not efficacy. 2013: FDA confirmed the 2008 withdrawal was not safety-related, preserving the possibility of generic approvals. Post-2008: Widely used as a compounded medication through 503A pharmacies for adult anti-aging and GH deficiency management. September 2023: FDA placed sermorelin on Category 2 (restricting compounding). Later 2024/early 2026: Sermorelin reportedly returned to Category 1 status before the broader HHS reclassification. Status in flux as of May 2026.

Why It's Different From GHRPs

Sermorelin activates the GHRH receptor (GHRHR), not the ghrelin receptor (GHS-R1a). This receptor specificity means: (1) No cortisol or ACTH co-elevation. (2) No prolactin elevation. (3) No appetite stimulation. (4) Somatostatin feedback is fully preserved — when GH levels rise sufficiently, hypothalamic somatostatin release increases and naturally limits the GH pulse, creating a physiological ceiling. This feedback means sermorelin cannot produce supraphysiological GH levels by dose escalation. It is mechanistically impossible to overdose in the way that exogenous rhGH overdose is possible.

The Somatostatin Safety Ceiling

The most important pharmacological feature of sermorelin for clinical use. Somatostatin is the hypothalamic hormone that inhibits GH release. When sermorelin stimulates the pituitary, the resulting GH elevation feeds back to the hypothalamus, increasing somatostatin release, which dampens the pituitary's response to further sermorelin stimulation. This negative feedback loop operates continuously during sermorelin therapy: if you take too much sermorelin, the somatostatin response prevents supraphysiological GH. Exogenous rhGH bypasses this mechanism entirely — rhGH is delivered directly into circulation, has no somatostatin feedback constraint, and genuinely can produce excessive GH levels. This ceiling is why sermorelin has a fundamentally different safety profile from exogenous HGH.

The Khorram 1994 Key Trial

Khorram O, Laughlin GA, Yen SS. (1997, JCEM): 19 healthy adults aged 55-71, GHRH analog (10 mcg/kg/night SubQ) for 16 weeks after 4-week placebo run-in. Results: significant increases in nocturnal GH and IGF-1 in both men and women; men experienced average +1.26 kg lean body mass increase; improved insulin sensitivity in men; improved subjective well-being. Adverse events: only transient facial flushing from injections. Grade B evidence (small n, single-blind, analog not sermorelin specifically). The most frequently cited aging-specific human trial for GHRH class compounds.

Sermorelin vs CJC-1295

Both activate GHRHR — sermorelin is the direct GHRH(1-29) fragment; CJC-1295 is a modified analog with 4 amino acid substitutions improving stability and extending half-life. Sermorelin t1/2: ~10-12 minutes. CJC-1295 (no DAC) t1/2: ~30 minutes. CJC-1295 with DAC t1/2: ~5-8 days (albumin binding). Sermorelin produces a brief, physiological GH pulse aligned with natural GHRH rhythm. CJC-1295 produces a longer pulse (no DAC) or sustained GH elevation (with DAC). For the most physiological GH pulsatility — the closest analog to what the hypothalamus does naturally — sermorelin's short half-life is an advantage. For clinical convenience and reduced injection frequency, CJC-1295 (especially with DAC) wins.

WADA Status

S2 — Peptide Hormones, Growth Factors, Related Substances and Mimetics. Banned at all times. Any competitive athlete in a tested sport: absolute prohibition.

Simple view

Need the deep dive?

The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.

Alternatives

Compare nearby options

Browse this class Compare 4 side by side →

AOD-9604

Same class · Peptide

Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.

CIT Stack

Same class · GHRH Analog

GH stack plus tesamorelin: a community combination built from GH-axis peptides with different regulatory identities, not a single FDA-approved product.

Tesamorelin